Pires L A, Lehmann M H, Buxton A E, Hafley G E, Lee K L
St. John Hospital and Medical Center and Wayne State University School of Medicine, Detroit, Michigan 48236, USA.
J Am Coll Cardiol. 2001 Oct;38(4):1156-62. doi: 10.1016/s0735-1097(01)01482-6.
The goal of this study was to describe the influence of the clinical setting (in-hospital vs. out-of-hospital) in which nonsustained ventricular tachycardia (NSVT) is discovered on the rate of inducibility of sustained ventricular tachycardia (VT), arrhythmic events and survival in patients with coronary artery disease (CAD) and left ventricular (LV) dysfunction.
In-hospital presentation of sustained VT is independently associated with lower long-term overall survival. The impact of the clinical setting in which NSVT is documented is unknown.
In the Multicenter Unsustained Tachycardia Trial (MUSTT), designed to assess the benefit of randomized antiarrhythmic therapy guided by electrophysiologic testing in patients with asymptomatic NSVT, CAD and LV dysfunction, eligible patients were enrolled irrespective of the setting in which the index arrhythmia was discovered. In this retrospective analysis, we compared the rate of VT inducibility and outcome of MUSTT-enrolled patients with in-hospital versus out-of-hospital presentation of NSVT.
Monomorphic sustained VT was induced in 35% and 28% of the patients whose index NSVT occurred in-hospital and out-of-hospital, respectively (adjusted p = 0.006). Cardiac arrest or death due to arrhythmia at two- and five-year follow-ups were 14% and 28% for untreated patients with in-hospital-identified NSVT and 11% and 21% for the out-of-hospital group (adjusted p = 0.10). Overall mortality rates at two- and five-year follow-ups were 24% and 48% for inpatients and 18% and 38% for outpatients (adjusted p = 0.018). In patients randomized to antiarrhythmic therapy, there was no significant interaction between patient status (in-hospital vs. out-of-hospital) and treatment impact on the rates of total mortality (p = 0.98) and arrhythmic events (p = 0.08).
In patients with CAD and impaired LV function, asymptomatic NSVT identified in-hospital, compared with that identified out-of-hospital, is associated with a higher rate of induction of sustained VT and overall mortality. Therefore, in similar patients, the clinical setting in which NSVT is discovered should be taken into account when formulating patient risk, treatment and clinical trial design.
本研究的目的是描述发现非持续性室性心动过速(NSVT)的临床环境(院内与院外)对冠心病(CAD)和左心室(LV)功能障碍患者持续性室性心动过速(VT)的诱发率、心律失常事件及生存率的影响。
持续性VT的院内表现与较低的长期总体生存率独立相关。记录NSVT的临床环境的影响尚不清楚。
在多中心非持续性心动过速试验(MUSTT)中,该试验旨在评估无症状NSVT、CAD和LV功能障碍患者在电生理测试指导下进行随机抗心律失常治疗的益处,符合条件的患者无论首次心律失常是在何种环境下发现均纳入研究。在这项回顾性分析中,我们比较了MUSTT研究中NSVT表现为院内和院外的患者的VT诱发率和结局。
首次NSVT发生在院内和院外的患者中,分别有35%和28%诱发出单形性持续性VT(校正p = 0.006)。在两年和五年随访时,未经治疗的院内确诊NSVT患者因心律失常导致的心脏骤停或死亡分别为14%和28%,院外组为11%和21%(校正p = 0.10)。两年和五年随访时的总体死亡率,住院患者分别为24%和48%,门诊患者为18%和38%(校正p = 0.018)。在随机接受抗心律失常治疗的患者中,患者状态(院内与院外)与治疗对总死亡率(p = 0.98)和心律失常事件(p = 0.08)发生率的影响之间没有显著交互作用。
在CAD和LV功能受损的患者中,与院外发现的无症状NSVT相比,院内发现的与持续性VT诱发率和总体死亡率较高相关。因此,在类似患者中,制定患者风险、治疗方案和临床试验设计时应考虑发现NSVT的临床环境。